An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Transplantation of an individual's own tissue from one site to another site.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7)
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Inorganic or organic compounds that contain the basic structure RB(OH)2.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
The farthest or outermost projections of the body, such as the HAND and FOOT.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
A mutant strain of Rattus norvegicus without a thymus and with depressed or absent T-cell function. This strain of rats may have a small amount of hair at times, but then lose it.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
An anti-inflammatory 9-fluoro-glucocorticoid.
An alkylating agent of value against both hematologic malignancies and solid tumors.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
A group of alkylating agents derived from mustard gas, with the sulfur replaced by nitrogen. They were formerly used as toxicants and vesicants, but now function as antineoplastic agents. These compounds are also powerful mutagens, teratogens, immunosuppressants, and carcinogens.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A 3:1 mixture of alfaxalone with alfadolone acetate that previously had been used as a general anesthetic. It is no longer actively marketed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1445)
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA.
Drugs used for their actions on histaminergic systems. Included are drugs that act at histamine receptors, affect the life cycle of histamine, or affect the state of histaminergic cells.

L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. (1/1170)

PET with L-[1-11C]-tyrosine (TYR) was investigated in patients undergoing hyperthermic isolated limb perfusion (HILP) with recombinant tumor necrosis factor alpha (rTNF-alpha) and melphalan for locally advanced soft-tissue sarcoma and skin cancer of the lower limb. METHODS: Seventeen patients (5 women, 12 men; age range 24-75 y; mean age 52 y) were studied. TYR PET studies were performed before HILP and 2 and 8 wk afterwards. The protein synthesis rates (PSRs) in nanomoles per milliliter per minute were calculated. After final PET studies, tumors were resected and pathologically examined. Patients with pathologically complete responses (pCR) showed no viable tumors after treatment. Those with pathologically partial responses (pPR) showed various amounts of viable tumors in the resected tumor specimens. RESULTS: Six patients (35%) showed a pCR and 11 patients (65%) showed a pPR. All tumors were depicted as hot spots on PET studies before HILP. The PSR in the pCR group at 2 and 8 wk after perfusion had decreased significantly (P < 0.05) in comparison to the PSR before HILP. A significant difference was found in PSR between the pCR and pPR groups at 2 and at 8 wk (P < 0.05). Median PSR in nonviable tumor tissue was 0.62 and ranged from 0.22 to 0.91. With a threshold PSR of 0.91, sensitivity and specificity of TYR PET were 82% and 100%, respectively. The predictive value of a PSR > 0.91 for having viable tumor after HILP was 100%, whereas the predictive value of a PSR < or = 0.91 for having nonviable tumor tissue after HILP was 75%. The 2 patients in the pPR groups with a PSR < 0.91 showed microscopic islets of tumor cells surrounded by extensive necrosis on pathological examination. CONCLUSION: Based on the calculated PSR after HILP, TYR PET gave a good indication of the pathological outcome. Inflammatory tissue after treatment did not interfere with viable tumor on the images, suggesting that it may be worthwhile to pursue TYR PET in other therapy evaluation settings.  (+info)

In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. (2/1170)

Isolated perfusion of the extremities with high-dose tumour necrosis factor alpha (TNF-alpha) plus melphalan leads to dramatic tumour response in patients with irresectable soft tissue sarcoma or multiple melanoma in transit metastases. We developed in vivo isolated organ perfusion models to determine whether similar tumour responses in solid organ tumours can be obtained with this regimen. Here, we describe the technique of isolated kidney perfusion. We studied the feasibility of a perfusion with TNF-alpha and assessed its anti-tumour effects in tumour models differing in tumour vasculature. The maximal tolerated dose (MTD) proved to be only 1 microg TNF-alpha. Higher doses appeared to induce renal failure and a secondary cytokine release with fatal respiratory and septic shock-like symptoms. In vitro, the combination of TNF-alpha and melphalan did not result in a synergistic growth-inhibiting effect on CC 531 colon adenocarcinoma cells, whereas an additive effect was observed on osteosarcoma ROS-1 cells. In vivo isolated kidney perfusion, with TNF-alpha alone or in combination with melphalan, did not result in a significant anti-tumour response in either tumour model in a subrenal capsule assay. We conclude that, because of the susceptibility of the kidney to perfusion with TNF-alpha, the minimal threshold concentration of TNF-alpha to exert its anti-tumour effects was not reached. The applicability of TNF-alpha in isolated kidney perfusion for human tumours seems, therefore, questionable.  (+info)

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. (3/1170)

Integrin-mediated adhesion influences cell survival and may prevent programmed cell death. Little is known about how drug-sensitive tumor cell lines survive initial exposures to cytotoxic drugs and eventually select for drug-resistant populations. Factors that allow for cell survival following acute cytotoxic drug exposure may differ from drug resistance mechanisms selected for by chronic drug exposure. We show here that drug-sensitive 8226 human myeloma cells, demonstrated to express both VLA-4 (alpha4beta1) and VLA-5 (alpha5beta1) integrin fibronectin (FN) receptors, are relatively resistant to the apoptotic effects of doxorubicin and melphalan when pre-adhered to FN and compared with cells grown in suspension. This cell adhesion mediated drug resistance, or CAM-DR, was not due to reduced drug accumulation or upregulation of anti-apoptotic Bcl-2 family members. As determined by flow cytometry, myeloma cell lines selected for drug resistance, with either doxorubicin or melphalan, overexpress VLA-4. Functional assays revealed a significant increase in alpha4-mediated cell adhesion in both drug-resistant variants compared with the drug-sensitive parent line. When removed from selection pressure, drug-resistant cell lines reverted to a drug sensitive and alpha4-low phenotype. Whether VLA-4-mediated FN adhesion offers a survival advantage over VLA-5-mediated adhesion remains to be determined. In conclusion, we have demonstrated that FN-mediated adhesion confers a survival advantage for myeloma cells acutely exposed to cytotoxic drugs by inhibiting drug-induced apoptosis. This finding may explain how some cells survive initial drug exposure and eventually express classical mechanisms of drug resistance such as MDR1 overexpression.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (4/1170)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). (5/1170)

Tumour-selective acidification is of potential interest for enhanced therapeutic gain of pH sensitive drugs. In this study, we investigated the feasibility of a tumour-selective reduction of the extracellular and intracellular pH and their effect on the tumour response of selected anti-cancer drugs. In an in vitro L1210 leukaemic cell model, we confirmed enhanced cytotoxicity of chlorambucil at low extracellular pH conditions. In contrast, the alkylating drugs melphalan and cisplatin, and bioreductive agents mitomycin C and its derivative EO9, required low intracellular pH conditions for enhanced activation. Furthermore, a strong and pH-independent synergism was observed between the pH-equilibrating drug nigericin and melphalan, of which the mechanism is unclear. In radiation-induced fibrosarcoma (RIF-1) tumour-bearing mice, the extracellular pH was reduced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) or its analogue benzylguanidine (BG) plus glucose. To simultaneously reduce the intracellular pH, MIBG plus glucose were combined with the ionophore nigericin or the Na+/H+ exchanger inhibitor amiloride and the Na+-dependent HCO3-/Cl- exchanger inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS). Biochemical studies confirmed an effective reduction of the extracellular pH to approximately 6.2, and anti-tumour responses to the interventions indicated a simultaneous reduction of the intracellular pH below 6.6 for at least 3 h. Combined reduction of extra- and intracellular tumour pH with melphalan increased the tumour regrowth time to 200% of the pretreatment volume from 5.7 +/- 0.6 days for melphalan alone to 8.1 +/- 0.7 days with pH manipulation (P < 0.05). Mitomycin C related tumour growth delay was enhanced by the combined interventions from 3.8 +/- 0.5 to 5.2 +/- 0.5 days (P < 0.05), but only in tumours of relatively large sizes. The interventions were non-toxic alone or in combination with the anti-cancer drugs and did not affect melphalan biodistribution. In conclusion, we have developed non-toxic interventions for sustained and selective reduction of extra- and intracellular tumour pH which potentiated the tumour responses to selected anti-cancer drugs.  (+info)

Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. (6/1170)

Transplantation after high-dose chemotherapy prolongs survival in patients with multiple myeloma compared with standard therapy. It is unclear whether the optimal timing of transplantation is immediately after induction chemotherapy or whether stem cells may be cryopreserved for transplantation at subsequent progression or relapse. In this study, stem cells were collected within 6 months of diagnosis, followed by transplantation only at progression of myeloma. One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved. Eleven had transplants early in the disease after they demonstrated failure to respond to primary therapy. The remaining 107 were eligible for transplants when there was evidence of progressive disease. Of the 118 patients, 67 had transplants, nine died of progressive disease before transplantation, and 42 remain alive in plateau phase. The median survival of the group is 58.5 months; 67 are alive. Serum beta2-microglobulin, bone marrow labeling index (S phase), and hemoglobin level predicted overall survival (P < 0.006, P < 0.001, and P < 0.01, respectively). We conclude that early cryopreservation of blood stem cells followed by transplantation at progression is a feasible approach to therapy in patients with myeloma. The underlying biology of the disease has a greater impact on survival than the timing of transplantation. A prospective randomized trial is required to answer definitively the question of the optimal timing of blood cell transplantation.  (+info)

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. (7/1170)

A patient with a stage IV mantle cell lymphoma (according to the REAL classification) was treated with high-dose chemotherapy and autologous bone marrow transplantation. One year later while on alpha-interferon immunotherapy she suffered from progressive loss of short-term memory and reported difficulties in recognizing objects. Magnetic resonance imaging (MRI) showed a vast ring-enhancing lesion of the left postcentral parietal area. Serial stereotactic biopsies disclosed progressive multifocal leukoencephalopathy without JC-virus in the cerebrospinal fluid. Therapy with subcutaneous interleukin-2 (IL-2) every other day and intrathecal cytarabine once a week was started. After 4 weeks the patient refused further treatment. Nevertheless her condition improved over the next 8 months and MRI scans showed a marked improvement in the lesions.  (+info)

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. (8/1170)

The idiotype (Id) determinant on the multiple myeloma (MM) protein can be regarded as a tumor-specific marker. Immunotherapy directed at the MM Id may stem the progression of this disease. We report here on the first 12 MM patients treated at our institution with high-dose therapy and peripheral blood stem cell transplantation (PBSCT) followed by Id immunizations. MM patients received PBSCT to eradicate the majority of the disease. PBSCT produced a complete response in 2 patients, a partial response in 9 patients and stable disease in 1 patient. Three to 7 months after high-dose therapy, patients received a series of monthly immunizations that consisted of two intravenous infusions of Id-pulsed autologous dendritic cells (DC) followed by five subcutaneous boosts of Id/keyhole limpet hemocyanin (KLH) administered with adjuvant. Between 1 and 11 x 10(6) DC were obtained by leukapheresis in all patients even after PBSCT. The administration of Id-pulsed DC and Id/KLH vaccines were well tolerated with patients experiencing only minor and transient side effects. Two of 12 patients developed an Id-specific, cellular proliferative immune response and one of three patients studied developed a transient but Id-specific cytotoxic T-cell (CTL) response. Eleven of the 12 patients generated strong KLH-specific cellular proliferative immune responses showing the patients' immunocompetence at the time of vaccination. The two patients who developed a cellular Id-specific immune response remain in complete remission. Of the 12 treated patients, 9 are currently alive after autologous transplantation with a minimum follow-up of 16 months, 2 patients died because of recurrent MM and 1 patient succumbed to acute leukemia. These studies show that patients make strong anti-KLH responses despite recent high-dose therapy and that DC-based Id vaccination is feasible after PBSCT and can induce Id-specific T-cell responses. Further vaccine development is necessary to increase the proportion of patients that make Id-specific immune responses. The clinical benefits of Id vaccination in MM remain to be determined.  (+info)

TY - JOUR. T1 - Prevention of the development of melphalan resistance in vitro by selenite. AU - Caffrey, Paula B.. AU - Zhu, Ming. AU - Frenkel, Gerald D.. PY - 1998/1/1. Y1 - 1998/1/1. N2 - Exposure of A2780 human ovarian tumor cells to a low concentration of melphalan in vitro for 7 d results in the development of melphalan resistance, which is dependent on elevated cellular levels of glutathione and glutathione S-transferase. The inclusion of selenite (at concentrations as low as 0.2 μM) during the exposure to melphalan completely prevented the development of resistance. Selenite did not prevent the melphalan-induced increase in glutathione, but it did prevent the increase in the activity of glutathione S-transferase. It also prevented the increase in the expression of the glutathione S-transferase gene, suggesting that this may be the mechanism by which it prevents the development of melphalan resistance. The results of this in vitro study suggest that selenite may prove to be useful in ...
In this study the investigators are comparing this standard regimen to the newly established regimen of melphalan and bortezomib.. Conditioning Regimens:. Treatment arm A Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.. Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.. Dosing will be based on body surface area calculated using actual body weight. Stem cell infusion:. Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.. Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least).. Treatment arm B. Bortezomib:. Bortezomib is administered by rapid I.V. push (over ...
Define L-phenylalanine mustard. L-phenylalanine mustard synonyms, L-phenylalanine mustard pronunciation, L-phenylalanine mustard translation, English dictionary definition of L-phenylalanine mustard. n a drug, C13H18Cl2N2O2, used to treat myeloid leukaemia Noun 1. melphalan - antineoplastic drug used to treat multiple myeloma and some other malignancies...
PRIMARY OBJECTIVES:. I. Compare the complete response (CR) and near CR rate in patients undergoing autologous stem cell transplant (ASCT) using melphalan 280 mg/m^2 or melphalan 200 mg/m^2.. SECONDARY OBJECTIVES:. I. Compare toxicities between patients receiving amifostine and melphalan 280 mg/m^2 or melphalan 200 mg/m^2.. OUTLINE: Patients are randomized to 1 of 2 treatment arms.. INDUCTION THERAPY:. ARM I (HIGH DOSE MELPHALAN AND AMIFOSTINE): Patients receive amifostine intravenously (IV) over 3-5 minutes on days -3 and -2 followed by high-dose melphalan IV over 15-30 minutes on day 2.. ARM II (LOW DOSE MELPHALAN AND AMIFOSTINE): Patients receive amifostine as in arm I and melphalan as in arm I at a lower dose.. AUTOLOGOUS OR SYNGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT): At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.. Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are ...
In a phase III trial reported in The New England Journal of Medicine, Palumbo et al found that consolidation therapy with high-dose melphalan plus autologous stem cell transplantation improved progression-free survival and overall survival compared with melphalan/prednisone/lenalidomide (Revlimid) consolidation and that lenalidomide maintenance vs no maintenance improved progression-free survival in patients ≤ 65 years newly diagnosed with multiple myeloma.. Study Details. In this open-label trial, 273 patients aged ≤ 65 years with newly diagnosed multiple myeloma from 62 centers in Israel and Italy were randomly assigned between November 2007 and July 2009 to receive high-dose melphalan (200 mg/m2) followed by autologous stem cell transplantation (n = 141) or melphalan/prednisone/lenalidomide consolidation (n = 132) after induction therapy with lenalidomide and dexamethasone. Of these, a total of 251 were further randomly assigned to lenalidomide maintenance after high-dose melphalan ...
BACKGROUND AND OBJECTIVES: Since optimal collection of peripheral blood progenitor cells (PBPC) remains crucial for high-dose therapy in patients with multiple myeloma (MM) in relapse phase or refractory to chemotherapy, we evaluated several variables that may influence mobilization. DESIGN AND METHODS: Eighty-nine patients who underwent a standard mobilization procedure with cyclophosphamide (3 g/m2) and growth factors entered the study. A composite collection totalling at least 2x106 CD34+/kg was defined as a sufficient yield: 59 patients achieved an adequate collection. A reliable factor to predict adequate yields was prior therapy: an adequate collection was obtained in 92% of patients treated with conventional non-alkylating therapy (VAD-based regimens), in 56% treated with oral melphalan and in 23% who had received intravenous melphalan. RESULTS: The three groups were similar for most clinical features. After adjustment for several potential confounders, the probability of an adequate PBPC ...
Taylor, P. R. A., Jackson, G. H., Lennard, A. L., Lucraft, H. H., Proctor, S. J., Abela, M., Angus, B., Branson, A. N., Browning, N. M., Cartner, R., Carey, P. J., Galloway, M. J., Chandler, J. C., Condie, P., Dewar, M., Evans, R. G. B., Finney, R. D., Goff, D., Hamilton, P. J ...
TY - JOUR. T1 - Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation. T2 - A prospective study of 22 patients with hematologic malignancies. AU - Rodriguez, Roberto. AU - Parker, P.. AU - Nademanee, A.. AU - Smith, D.. AU - ODonnell, M. R.. AU - Stein, A.. AU - Snyder, D. S.. AU - Fung, H. C.. AU - Krishnan, A. Y.. AU - Popplewell, L.. AU - Cohen, S.. AU - Somlo, G.. AU - Angelopoulou, M.. AU - Al-Kadhimi, Z.. AU - Falk, P. M.. AU - Spielberger, R.. AU - Kogut, N.. AU - Sahebi, F.. AU - Senitzer, D.. AU - Slovak, M.. AU - Schriber, J.. AU - Forman, S. J.. PY - 2004/6/1. Y1 - 2004/6/1. N2 - In an attempt to decrease toxicity in high-risk patients undergoing unrelated donor hematopoietic stem cell transplantation (URD HSCT), we tested a combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis with the reduced-intensity conditioning regimen fludarabine/melphalan ...
Isolated pelvic perfusion (IPP) can be used to treat unresectable melanoma metastases of the pelvis. IPP can be performed either by surgical or percutaneous approaches, using different balloon catheters. The aim of this study was to examine whether the surgical and percutaneous approaches were comparable with respect to tumor drug exposure in the pelvis. A pharmacokinetic study was performed in 5 melanoma patients treated with surgical IPP and five with percutaneous IPP. Both groups received melphalan at the dose of 30 mg/m2. Melphalan pharmacokinetic analyses were performed and the main parameter used to evaluate pelvic tumor drug-exposure was the ratio of areas under the melphalan plasma concentration curves in the pelvis and the systemic compartment, during the perfusion time (AUC0 to 20). Non-parametric Mann-Whitney tests were employed for statistical comparisons. The median and interquartile range (IQR) values of the ratios between melphalan AUC0 to 20 in pelvic and systemic compartments were 7.9
Another amino acid-like drug is the antineoplastic agent melphalan. Tumor cells spend less time in resting phases than normal cells so at any given time, they are more likely to be metabolically active than most normal host cells. The rationale behind incorporating an alkylating function in a molecule resembling a primary cellular metabolite was to get a greater safety margin by fooling tumor cells into taking up the toxin preferentially. ...
Search Indian Alphalan Melphalan Manufacturers and Suppliers Details - Contact to Alphalan Melphalan Exporters in India, Alphalan Melphalan Wholesalers, Alphalan Melphalan Distributors and Traders from India.
The Role of High Dose Chemotherapy With Autologous Stem Cell Rescue in Multiple Myeloma in the Era of Conventional Cytotoxic Chemotherapy. Before the introduction of proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs), high dose melphalan with ASCT following induction therapy was considered the standard approach for transplant-eligible patients with newly diagnosed MM. The first randomized controlled trial from the Intergroupe Francais du Myelome (IFM90), published in 1996, randomized newly diagnosed MM patients to an older chemotherapy regimen (vincristine/carmustine, cyclophosphamide, prednisone alternating with carmustine, vincristine, adriamycin, prednisone; VMCP/BVAP) for 12 cycles versus 4 to 6 cycles of VMCP/BVAP followed by high dose therapy with autologous bone marrow transplant.1 Those patients randomized to the transplant arm compared with the high dose chemotherapy arm had a superior 5-year event-free survival (EFS) (28% versus 10%, respectively, P = .01) and OS (52% ...
Melphalan is used as a "palliative" treatment to relieve symptoms of multiple myeloma (a type of blood cancer) or a certain type of ovarian cancer. Melphalan injection is used as a "conditioning" treatment for multiple myeloma before you receive a stem cell transplant. Melphalan may also be used for...
All information about the latest scientific publications of the Clínica Universidad de Navarra. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
The results show that the activity of the dipeptide mustards is highly dependent on intracellular hydrolysis, which result in rapid intrACEllular release of the alkylating unit in cells with high enzymatic activity. Recently, we presented a series of melphalan containing di- and tripeptides with high cytotoxic activity and J1 (l-melphalanyl-p-l-fluorophenylalanine ethyl ester) was identified as one of the most interesting compounds. It was speculated that the increased activity compared to melphalan itself, demonstrated both in vitro and in vivo, resided in increased transport over the tumour cell membrane and/or hydrolytic cleavage and liberation of melphalan inside the cells. Indeed, overexpression of hydrolytic enzymes like peptidases, esterases and proteases has been described in several types of human malignancies, thus providing a target for selective chemotherapy. In this work, the details of the increased activity was further investigated and potential tumour selectivity is discussed. The
PEPAXTO is contraindicated in patients with a history of serious allergic reaction to melphalan flufenamide or melphalan.. PEPAXTO may cause thrombocytopenia, which may lead to hemorrhage. Monitor platelets at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first 2 months of treatment with PEPAXTO. Do not administer PEPAXTO if the platelet count is less than 50 x 109/L. Withhold PEPAXTO until platelet count is 50 x 109/L or greater and resume at same or reduced dose based on duration of interruption. Adjust dose and/or dose schedule based on signs and symptoms of bleeding.. PEPAXTO may cause neutropenia, which may lead to infection. Monitor neutrophil counts at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first 2 months of treatment with PEPAXTO. Do not administer PEPAXTO if absolute neutrophil count is less than 1 x 109/L. Withhold PEPAXTO until absolute neutrophil count is 1 x 109/L or greater and resume ...
Solid tumors provide an environment conducive to bioreduction due to hypoxia and overexpression of bioreductive enzymes. Therefore, TDDS were designed with various substituents to modulate bioreductive activation. TDDS contain a quinone-based carrier coupled to the model drug, melphalan methyl ester (MME). Controlled bioreductive activation of TDDS can lead to specific drug release only at the tumor sites and hence reduce toxicity during systemic distribution. The rate and extent of bioreductive activation of TDDS was determined in presence of DT-diaphorase, xanthine oxidase, human breast tumor cells (MCF-7) and colon tumor cells (Caco-2). Stability of TDDS under aqueous buffer conditions and in the presence of glutathione was also evaluated. Anticancer activity of TDDS was determined based on alkylating activity, cytotoxicity and apoptotic induction in both the tumor cell lines. Results show that all TDDS especially CH3-TDDS improved stability of melphalan under pH 7.4. H-TDDS possessed ...
The use of stem cell transplantion (SCT) therapy has also been explored in patients WM. Desikan et al177 reported their initial experience of high-dose chemotherapy and autologous stem cell transplant, which has more recently been updated by Munshi et al.178 Their studies involved eight previously treated WM patients between the ages of 45 and 69 years, who received either melphalan at 200mg/m2 (n = 7) or melphalan at 140mg/m2 along with total body irradiation. Stem cells were successfully collected in all eight patients, although a second collection procedure was required for two patients who had extensive previous nucleoside analogue exposure. There were no transplant related mortalities and toxicities were manageable. All eight patients responded, with 7 of 8 patients achieving a major response, and one patient achieving a complete response with durations of response raging from 5+ to 77+ months. Dreger et al179 investigated the use of the DEXA-BEAM (dexamethasone, BCNU, etoposide, ...
Fludarabine, Melphalan, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders…
The current studies demonstrate that MOPC-315 tumor cells secrete large amounts of interleukin-10 (IL-10), which contributes to the inhibitory activity of MOPC-315 culture supernatants for the in vitro generation of antitumor cytotoxicity by MOPC-315-immune spleen cells. Moreover, addition of neut …
Alkeran tablets and injection contain the active ingredient melphalan, which is a type of chemotherapy medicine to treat cancer called an alkylating agent.
Generic name Melphalan hydrochloride Pronunciation MEL-fa-lan HIGH-droe-KLOR-ide Brand name(s), other common name(s) EvomelaTM Drug type Alkylating agent How the drug is given
Citation: Shelby, M.D., Gulati, D.K., Tice, R.R., and Wojciechowski, J.P. Results of tests for micronuclei and chromosomal aberrations in mouse bone marrow cells with the human carcinogens 4-aminobiphenyl, treosulphan, and melphalan. Environ. Molec. Mutagen. Vol. 13 (1989) 339- ...
ALKERAN (Melphalan) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
Buy Melphalan Hydrochloride online at LGC Standards. High quality reference standards for the most reliable pharmaceutical testing.
We have isolated cis-diamminedichloroplatinum(II) (CDDP)-resistant variants, C/CDP-1 and C/CDP-2, from a Chinese hamster ovary (CHO) cell line after a stepwise exposure to increasing concentrations of CDDP, and a CDDP-sensitive revertant, R-1, from C/CDP-2 after continuous incubation for 5 months in the absence of CDDP. C/CDP-1 and C/CDP-2 showed 7- and 10-fold higher resistance to CDDP, respectively, compared to CHO cells. C/CDP-2 was cross-resistant to carboplatin, l-phenylalanine mustard (melphalan), and CdSO4, but not to other anticancer agents. Alkaline elution of DNA showed an increased amount of DNA interstrand cross-linking formation in CHO cells, but not in C/CDP-2 cells, when CHO and C/CDP-2 cells were cultured with CDDP. By contrast, alkaline elution of DNA showed increased formation of DNA cross-links when nuclei of C/CDP-2 cells were treated with CDDP. The activity of glutathione S-transferase (GST) of C/CDP-1 and C/CDP-2 was 4- and 6-fold higher than that of CHO cells, ...
Introduction. High dose melphalan 200mg/m2 (MEL200) followed by autologous stem cell transplantation (ASCT) is the standard of care for fit patients with Multiple Myeloma (MM). Bendamustine has been shown to induce responses in MM resistant to other alkylating agents. Our prior Phase I trial, adding bendamustine to MEL200, demonstrated no additional toxicity above that expected with MEL200 alone (Mark et. al. BBMT 2013). A phase 2 trial of bendamustine/MEL200 conditioning was conducted to evaluate treatment efficacy. Objective and Methods. This single arm, open-label, phase II study was designed to establish the efficacy of Bendamustine (225 mg/m2) in combination with MEL200 in patients undergoing first ASCT for MM. Patients 18 to 75 years with confirmed MM, prior induction therapy, adequate mobilization (at least 2x106 of CD34+ hematopoietic stem cells), Karnofsky performance status ,70% and life expectancy ,12 weeks were eligible for screening. Major exclusion criteria included ...
The combination of oral melphalan and dexamethasone is considered standard therapy for patients with light-chain amyloidosis ineligible for autologous stem cell transplantation. However, previous trials reported different rates of response and survival, mainly because of the different proportions of …
TY - JOUR. T1 - Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. AU - Libutti, Steven K.. AU - Bartlett, David L.. AU - Fraker, Douglas L.. AU - Alexander, H. Richard. PY - 2000. Y1 - 2000. N2 - Background: For a variety of histologies, the liver represents the only or the dominant site of metastatic disease. Regional treatment of the liver has the theoretic advantage of maximizing drug delivery while minimizing systemic toxicity. This article describes the technique of isolated hepatic perfusion using tumor necrosis factor and melphalan under conditions of moderate hyperthermia for the treatment of unresectable liver tumors. Study Design: Fifty patients with biopsy-proved unresectable primary or metastatic cancer to the liver were treated. Isolated hepatic perfusion was performed for 60 minutes under conditions of moderate hyperthermia during a laparotomy with inflow through the ...
Oligopeptides can be used to carry cytotoxic agents in cancer chemotherapy, using tumour-associated proteins as the molecular target for selectivity. During the seventies and eighties Peptichemio, a cocktail of six alkylating oligopeptides carrying m-L-sarcolysin, was investigated in a wide variety of human malignancies. Positive clinical results were suggested to result from rapid and effective DNA-crosslinking following uptake in neoplastic cells, but also from antimetabolic properties of the drug. Although m-L-sarcolysin never reached widespread clinical use, the well established para-isomer melphalan still, after nearly fifty years, has a place in cancer chemotherapy.. The present study was undertaken to synthesise the melphalan containing analogue of the tripeptide P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester, the main contributor to Peptichemios activity) and similar compounds, preferably dipeptides. The new compounds compared favourably with melphalan, m-L-sarcolysin ...
A case series of three patients by Francis et al. has investigated the response and toxicity of intravitreal melphalan treatment for non-vitreous retinoblastoma that was refractory to multiple-course ophthalmic artery chemosurgery (OAC). Patients Three eyes received a median of 7 weekly intravitreal melphalan injections (30μg/0.07cc). The toxicity of treatment was measured by electroretinogram (ERG) and the response to treatment was clinically evaluated. All eyes remained tumor-free at a median of 14 months follow-up. One eye was enucleated due to a vitreous hemorrhage that obscured fundus details. One eye had extinguished ERG recordings prior to injections and two eyes had a decrease in ERG responses over the intravitreal treatment course. The eye with subretinal seeding demonstrated marked retinopathy by ophthalmoscopy and fluorescein angiography and one eye was enucleated due to the development of a vitreous hemorrhage. This small case series highlights that non-vitreous disease that is ...
All information about the latest scientific publications of the Clínica Universidad de Navarra. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma
A number of strategies have been proposed to improve the outcome of ASCT. The three main strategies are to incorporate novel agents into the induction r
POEMS syndrome is a rare plasma cell dyscrasia. This study compared the responses to and survival of 347 POEMS syndrome patients given three first-line treatment regimens: autologous stem cell transplantation (ASCT, N = 165) and melphalan + dexamethasone (MDex, N = 79), or lenalidomide + dexamethasone (LDex, N = 103). After a median 45-month follow-up, overall hematologic complete remission (CRH) was 46.4%, vascular endothelial growth factor complete remission (CRV) was 55.1%, and neurological remission (RN) was 93.8%. CRH was better with ASCT (49.7%) than with MDex (37.7%, p = 0.001). CRV was better with ASCT (66.2%) than with MDex (38.5%, p = 0.001) or LDex (47.7%, p = 0.008). Differences in RN achieved by three regimens (91.5% vs. 100% vs. 93.8%, p = 0.234) were not significant. Overall 3-year progression-free survival (PFS) was 80.5% and overall 3-year overall survival (OS) was 90.8%. PFS was 87.6% with ASCT and 64.9% with LDex (p = 0.003). OS in the three regimens did not differ (p = 0.079). In
Background and Objective. High-dose sequential chemotherapy (HDS) has been given to patients with Hodgkins disease (HD) before autologous hematopoietic stem cell transplantation (HSCT), but its effectiveness has not been evaluated in comparison with less-aggressive regimens. In this study we compared HDS with a less-aggressive regimen as preparation to autologous HSCT in patients with HD. Design and Methods. Retrospective non-randomized comparison between patients receiving HDS (group 1, n=52) or a less-aggressive regimen (group 2, n=60). HDS consisted of the sequential administration of cyclophosphamide (7 g/m 2) and G-CSF (300 μg/day) with stem cell collection, methotrexate (8 g/m2) plus vincristine (1.4 mg/m2), and etoposide (2 g/m2). Group 2 patients received of 2 cycles of DHAP, followed by cyclophosphamide (1.5 g/m2) plus G-CSF and stem cell collection. Results. Group 1 patients were more likely to have stage IV (40% vs. 13%, p=0.001) and bulky disease (62% vs. 39%, p=0.02) at diagnosis. ...
Consolidation with melphalan and autologous stem-cell transplantation (ASCT) remains the preferred option in transplant-eligible multiple myeloma.
In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been usedsince the 1960s and is regarded as the standard of care in ver
Melphalan (US brand name Alkeran) is a chemotherapy drug commonly used to treat multiple myeloma. See common side effects and how its used.
Fingerprint Dive into the research topics of Combination therapy with Melphalan, Prednisone, and Thalidomide (MPT) for multiple myeloma. Together they form a unique fingerprint. ...
112 Patienten wurden im Rahmen von 2 prospektiven multizentrischen Phase-II Studien mit einer isolierten Extremitätenperfusion mit Tumornekrosefaktor (TNF) und Melphalan behandelt. Hiervon waren 49 Patienten an einem lokoregionär metastasierten Melanom und 63 Patienten an einem lokal fortgeschrittenen Weichgewebssarkom erkrankt. Bei Patienten mit regionären Metastasen eines Melanoms fand sich in 46 % eine komplette und in 20 % eine partielle Remission. Die mittlere lokoregionäre progressionsfreie Zeit war 32,3 Monate (Median 15,6 Monate). Sie war signifikant länger bei Patienten mit einer kompletten Remission (46,0 Monate, Median 30,2 Monate) im Vergleich zu Patienten mit einer partiellen Remission (15,2 Monate, Median 16,1 Monate) oder Patienten mit unverändertem Befund (7,2 Monate, Median 6,0 Monate). Die Gesamt-Überlebenszeit der Patienten mit Melanom betrug im Mittel 42,6 Monate (Median 24,4 Monate) und die 5-Jahres-Überlebensrate 42 %. Die klinische Ansprechrate der Patienten mit ...
112 Patienten wurden im Rahmen von 2 prospektiven multizentrischen Phase-II Studien mit einer isolierten Extremitätenperfusion mit Tumornekrosefaktor (TNF) und Melphalan behandelt. Hiervon waren 49 Patienten an einem lokoregionär metastasierten Melanom und 63 Patienten an einem lokal fortgeschrittenen Weichgewebssarkom erkrankt. Bei Patienten mit regionären Metastasen eines Melanoms fand sich in 46 % eine komplette und in 20 % eine partielle Remission. Die mittlere lokoregionäre progressionsfreie Zeit war 32,3 Monate (Median 15,6 Monate). Sie war signifikant länger bei Patienten mit einer kompletten Remission (46,0 Monate, Median 30,2 Monate) im Vergleich zu Patienten mit einer partiellen Remission (15,2 Monate, Median 16,1 Monate) oder Patienten mit unverändertem Befund (7,2 Monate, Median 6,0 Monate). Die Gesamt-Überlebenszeit der Patienten mit Melanom betrug im Mittel 42,6 Monate (Median 24,4 Monate) und die 5-Jahres-Überlebensrate 42 %. Die klinische Ansprechrate der Patienten mit ...
Health,...Launch represents first available generic equivalent of Alkeran(R) ... ...LAKE FOREST Ill. and NEWTOWN Pa. June 9 /- Bioniche P... ...,Bioniche,Pharma,and,Synerx,Pharma,Launch,Melphalan,Hydrochloride,for,Injection,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Bone marrow consists of several kinds of cells. These cells manufacture many chemicals known as proteins. One kind of bone marrow cell (plasma cell) makes a protein called amyloid that is produced in different forms. One form is lighter in weight than others. Abnormal plasma cells may produce too much light amyloid, which results in a disease called AL amyloidosis. This protein is then deposited in different organs, causing progressive disability and death. Without treatment, patients usually die within about a year. If amyloid deposits affect the heart, death occurs more rapidly (in about 5 months). Treatment with a drug called melphalan destroys abnormal plasma cells and, when given by mouth, can lengthen survival. A promising new approach to treatment involves giving high-dose melphalan intravenously. However, this approach also kills normal bone marrow cells, which must then be replaced. This is done by collecting a special type of cell (known as stem cells) from the patients bone marrow or ...
Background: Multiple myeloma (MM) is a B-cell malignancy, where malignant plasma cells clonally expand in the bone marrow of older people, causing significant morbidity and mortality. Typical clinical symptoms include increased serum calcium levels, renal insufficiency, anemia, and bone lesions. With standard therapies, MM remains incurable; therefore, the development of new drugs or immune cell-based therapies is desirable. To advance the goal of finding a more effective treatment for MM, we aimed to develop a reliable preclinical MM mouse model applying sensitive and reproducible methods for monitoring of tumor growth and metastasis in response to therapy. Material and Methods: A mouse model was created by intravenously injecting bone marrow-homing mouse myeloma cells (MOPC-315.BM) that expressed luciferase into BALB/c wild type mice. The luciferase in the myeloma cells allowed in vivo tracking before and after melphalan treatment with bioluminescence imaging (BLI). Homing of MOPC-315.BM ...
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. ...
Abstract. VTD as well as MPT chemotherapies have been known to be most active regimens in patients (pts) with MM. The objective of this study is to evaluate re
After the very high dose of chemotherapy (Melphalan) on Valentines Day and the Stem Cell Transplant on Day 0 (the birth of Munira, Version 2.0), the rest of the time in the hospital has been waiting for the stem cells to engraft, and for me to manage the devastating effects of the chemo. And what…
Cornelis J. H. van de Velde is the author of this article in the Journal of Visualized Experiments: Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Arian R. van Erkel is the author of this article in the Journal of Visualized Experiments: Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
This trial is assessing the efficacy and safety of bortezomib when used along with dexamethasone, melphalan, cisplatin, thalidomide and lenalidomide in lower
Melphalan is a DNA alkylating agent; induces cytotoxicity through the formation of stable interstrand and intrastrand crosslinks within DNA which inhibits growth of PC-3 cells (IC50 values are 0.074 and 0.77 μM for sequential dosing and single dosing respectively). Learn More ...
This talk will focus on the current literature associated with regional limb perfusion and provide technical details of performing regional limb perfusions in the field. In addition, cases and indications of use will be discussed along with common pitfalls or failures seen with the procedure that may lead to a failure in response to treatment. There will be a discussion of the prognosis seen with its use verses without. ...
While recent popular uprisings have had a tendency to be varied, uncertain or unexpected, they can be seen as standard bearers of the emergence (...)
Defty, CL; Marsden, JR (2012). "Melphalan in regional chemotherapy for locally recurrent metastatic melanoma". Current Topics ...
Evomela (melphalan) is an alkalyating drug for multiple myeloma. A number of drugs are currently investigated in clinical ...
Most chemotherapy is delivered intravenously, although a number of agents can be administered orally (e.g., melphalan, busulfan ... Dexamethasone along with either bortezomib or melphalan is commonly used as a treatment for AL amyloidosis. Recently, ... Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas ... melphalan) including CDDP could be reversed at least partially by the addition of heat. Chemotherapy is used in veterinary ...
Melphalan is a bifunctional alkylating agent frequently used in chemotherapy. Meiotic inter-strand DNA damages caused by ... melphalan can escape paternal repair and cause chromosomal aberrations in the zygote by maternal misrepair. Thus both pre- and ...
Other nitrogen mustards developed include cyclophosphamide, chlorambucil, uramustine, melphalan, and bendamustine. Bendamustine ...
The drugs for which it receives royalties include Kyprolis, Promacta, Melphalan and Baxdela. As of 2015, Ligand Pharmaceuticals ...
The EWOG-MDS study also involves cyclophosphamide and melphalan in its conditioning regimen. Post transplant management: ...
2008). "Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma" (PDF). N. Engl. J. Med. 359 (9): ... Treatment with bortezomib, melphalan, and prednisone had an estimated overall survival of 83% at 30 months, lenalidomide plus ... For these people, the standard of care has been chemotherapy with melphalan and prednisone. Recent studies among this ... such as melphalan, cyclophosphamide, thalidomide, or dexamethasone, alone or in combination), and a second ASCT. Later in the ...
Improvement has also been noted with autologous stem cell transplantation, and chemotherapy with melphalan. Chahin N, Selcen D ...
"Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma", News-Medical.Net, 20 July 2015, retrieved 6 ... NASDAQ: DCTH) a specialty pharmaceutical and medical device company manufactures melphalan. By 2011 the oral medications for ... melphalan (trade name Alkeran), busulfan, capecitabine). Delcath Systems, Inc. ( ...
EMA has also approved it to treat MM in combination with prednisone and/or melphalan. Orphan indications by the FDA include ...
High-dose melphalan in conjunction with autologous stem cell transplantation has been used in some patients. A regimen of ...
The four-drug combination helped in the increased overall remission rate, but was more toxigenic than melphalan. The four-drug ... regimen is more effective than melphalan in the management of advanced ovarian adenocarcinoma. ST8 suppression of ...
"Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma", News-Medical.Net, 20 July 2015, retrieved 6 ... melphalan (trade name Alkeran), busulfan, capecitabine). Delcath Systems, Inc. (NASDAQ: DCTH) a specialty pharmaceutical and ... medical device company manufactures melphalan.[83] By 2011 the oral medications for cancer patients represented approximately ...
Treatment with high dose melphalan, a chemotherapy agent, followed by stem cell transplantation has shown promise in early ... Chemotherapy and steroids, with melphalan plus dexamethasone, is mainstay treatment in AL people not eligible for transplant. ...
EMA has also approved it to treat MM in combination with prednisone and/or melphalan. Orphan indications by the FDA include ...
... is used as a first-line treatment in multiple myeloma in combination with dexamethasone or with melphalan and ... It was also evaluated whether thalidomide can be combined with melphalan and prednisone for patients with multiple myeloma. ... including doxorubicin and melphalan) concurrently. Thalidomide may interfere with various contraceptives, and hence it is ...
CS1 maint: discouraged parameter (link) "VELCADE as Initial Standard Therapy in multiple myeloma: Assessment with melphalan and ...
... melphalan, chlorambucil and chlormethine. Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and ...
... with neutrophil and platelet recovery in patients receiving autologous marrow transplantation after high-dose melphalan ...
People were randomized to receive either nine cycles of oral melphalan (M) plus prednisone (P) or MP plus bortezomib. People ... It was seen that bortezomib plus lenalidomide plus dexamethasone as well as bortezomib plus melphalan and prednisone may result ...
Hematological response rates to the dexamethasone/melphalan regimens have been reported to be in the 80% range with ... a corticosteroid such as dexamethasone plus an alkylating agents such as melphalan. Dosage regimens are selected on the basis ... neurological response rates approaching 100%. Patients successfully treated with the high-dose dexamethasone/melphalan regimen ...
... melphalan, chlorambucil and chlormethine. Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and ...
... polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan". ...
In France, three people died after being given cyclophosphamide, an alternative drug to Aspen's melphalan which had gone up in ...
It has been reported that clearance of lesions can be done with melphalan and cyclophosphamide alone or in combination with ...
Use under this protocol, usually with fludarabine and melphalan, was developed by oncologists at the University of Texas MD ...
... and melphalan (Alkeran). In 1952 the ICR's Eric Boyland had proposed that certain chemicals that cause cancer (carcinogens) ...
May 2005). "Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed ...
Melflufen, an experimental prodrug of melphalan. References[edit]. *^ "Melphalan". National Cancer Institute. Retrieved 4 ... Melphalan (trade name Alkeran, in former USSR also known as Sarcolysin) is a chemotherapy drug belonging to the class of ... "Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell ... Melphalan chemically alters the DNA nucleotide guanine through alkylation, and causes linkages between strands of DNA. This ...
Melphalan: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Melphalan is used to treat multiple myeloma (a type of cancer of the bone marrow). Melphalan is also used to treat a certain ... Before taking melphalan,. *tell your doctor and pharmacist if you are allergic to melphalan, any other medications, or any of ... Melphalan may increase the risk that you will develop other cancers. Talk with your doctor about the risks of taking melphalan. ...
Alkeran tablets and injection contain the active ingredient melphalan, which is a type of chemotherapy medicine to treat cancer ... Alkeran (melphalan). Alkeran tablets and injection contain the active ingredient melphalan, which is a type of chemotherapy ... Melphalan works by stopping the cancer cells from multiplying. It does this by binding to and damaging the DNA in the cancer ... Melphalan is mainly used in the treatment of bone marrow cancer (multiple myeloma), but may also sometimes be used to treat ...
Melphalan Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... When melphalan injection is given to treat multiple myleoma in people who are unable to take melphalan by mouth, it is usually ... Melphalan may increase the risk that you will develop other cancers. Talk with your doctor about the risks of taking melphalan. ... Before receiving melphalan injection,. *tell your doctor and pharmacist if you are allergic to melphalan, any other medications ...
Melphalan flufenamide is a peptidase enhanced cytotoxic (PEnC) that exerts a targeted delivery of melphalan in cells with high ... Compared to melphalan, melphalan flufenamide exhibits significantly higher in vitro and in vivo activity in several models of ... This suggests that melphalan flufenamide is rapidly and widely distributed to extravasal tissues, in which melphalan is formed ... Melphalan flufenamide rapidly disappeared from plasma after infusion, while melphalan typically peaked a few minutes after the ...
Melphalan - Generated on June 27, 2019. ©2019 Memorial Sloan Kettering Cancer Center. ... If you have an allergy to melphalan or any other part of this drug. ...
Generic name Melphalan hydrochloride Pronunciation MEL-fa-lan HIGH-droe-KLOR-ide Brand name(s), other common name(s) EvomelaTM ... Patients Disease Information Treatment Types of Treatment Chemotherapy and Other Drug Therapies Drug Listings Melphalan ...
MELPHALAN HYDROCHLORIDE (UNII: 1VXP4V453T) (MELPHALAN - UNII:Q41OR9510P) MELPHALAN. 50 mg in 10 mL. ... Each single use vial contains melphalan hydrochloride equivalent to 50 mg melphalan and 20 mg povidone. Melphalan hydrochloride ... PACKAGE LABEL - PRINCIPAL DISPLAY - Melphalan Hydrochloride Kit - Melphalan 50 mg Vial Label Panel. Melphalan Hydrochloride for ... PACKAGE LABEL - PRINCIPAL DISPLAY - Melphalan Hydrochloride Kit - Melphalan 50 mg Vial Carton Panel. Melphalan Hydrochloride ...
melphalan hydrochloride (UNII: 1VXP4V453T) (melphalan - UNII:Q41OR9510P) melphalan. 50 mg in 10 mL. ... Each single-use vial contains melphalan hydrochloride equivalent to 50 mg melphalan and 20 mg povidone. Melphalan hydrochloride ... Mean (±SD) peak melphalan plasma concentrations in myeloma patients given IV melphalan at doses of 10 or 20 mg/m2 were 1.2 ± ... The racemic (DL-) form is known as melphalan or sarcolysin. Melphalan is practically insoluble in water and has a pKa1 of ∼2.5 ...
Melphalan has been used as a drug along with HDAC-inhibitor JNJ-26481585 to treat multiple myeloma (MM) in cell lines and as a ... Melphalan powder Synonym: 4-. [Bis(2-. chloroethyl). amino]. -. L. -phenylalanine, L. -PAM, L. -Phenylalanine mustard ... Melphalan has been used as a drug along with HDAC-inhibitor JNJ-26481585 to treat multiple myeloma (MM) in cell lines and as a ... Melphalan also known as L-phenylalanine mustard is an alkylating agent. It belongs to the class of nitrogen mustards, which act ...
Make research projects and school reports about Melphalan easy with credible articles from our FREE, online encyclopedia and ... Melphalan Gale Encyclopedia of Cancer COPYRIGHT 2002 The Gale Group Inc.. Melphalan. Definition. Melphalan is an anticancer ( ... Melphalan should always be taken with plenty of fluids.. Melphalan can cause an allergic reaction in some people. Patients with ... Because melphalan is easily passed from mother to child through breast milk, breastfeeding is not recommended while melphalan ...
Although there is no specific information comparing use of melphalan in children with use in other age groups, this medicine is ... There is no specific information comparing the use of melphalan in the elderly with use in other age groups. ...
Current drugs shortage notification for Melphalan Tablets including reason for shortage, estimated resupply dates, and ... Melphalan Tablets. Last Updated: April 23, 2021. Status: Resolved. Products Affected - Description * *Alkeran oral tablet, Apo- ... Melphalan oral tablet, Alvogen, 2 mg, bottle, 50 count, NDC 47781-0200-50 ...
Melphalan is used to treat multiple myeloma (a type of blood cancer) and cancer of the ovary. Melphalan treats only the ... Melphalan is a cancer medication that interferes with the growth and spread of cancer cells in the body. ... Oral melphalan is a tablet you take by mouth. Injectable melphalan is injected into a vein through an IV. A healthcare provider ... What is melphalan?. Melphalan is a cancer medication that interferes with the growth and spread of cancer cells in the body. ...
Testing Status of Melphalan 11171-J. CASRN: 148-82-3. Related: TRANSGENIC MODEL EVALUATION (MELPHALAN). Formula: C13-H18-Cl2-N2 ... Citation: Russell, L.B., Hunsicker, P.R., and Shelby, M.D. Melphalan, a second chemical for which specific-locus mutation ... Dominant lethal and heritable translocation tests with chlorambucil and melphalan in male mice. Mutat. Res. 345: 167-180. (1995 ... Dominant lethal and heritable translocation tests with chlorambucil and melphalan in male mice. Mutat. Res. 345: 167-180. (1995 ...
Fresenius Kabi announced today the immediate availability in the United States of Melphalan Hydrochloride for Injection. ... Melphalan is leukemogenic in humans. Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should be ... About Melphalan Hydrochloride for Injection Melphalan Hydrochloride for Injection is indicated for the palliative treatment of ... This important safety information does not include all the information needed to use MELPHALAN HYDROCHLORIDE FOR INJECTION ...
Melphalan) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related ... Melphalan is leukemogenic in humans.. Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should be ... ALKERAN (melphalan) is available in tablet form for oral administration. Each film-coated tablet contains 2 mg melphalan and ... ALKERAN (melphalan) is supplied as white, film-coated, round, biconvex tablets containing 2 mg melphalan in amber glass bottles ...
Melphalan injection should only be used to treat people who are unable to take melphalan by mouth. Melphalan is in a class of ... Melphalan may increase the risk that you will develop other cancers. Talk with your doctor about the risks of taking melphalan. ... Before receiving melphalan injection, *tell your doctor and pharmacist if you are allergic to melphalan, any other medications ... Melphalan injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: *nausea ...
Get an overview of MELPHALAN HYDROCHLORIDE (injection, powder, lyophilized, for solution), including warnings and precautions, ...
Find user ratings and reviews for melphalan oral on WebMD including side effects and drug interactions, medication ... Read user comments about the side effects, benefits, and effectiveness of melphalan oral. ...
Food and Drug Administration Office of Orphan Products Development has granted Orphan Drug Designation for melphalan for the ... Additional analyses will be conducted to characterize the systemic exposure of melphalan administered by Melphalan/HDS, as well ... Melphalan granted FDA Orphan Drug Designation for treatment of cholangiocarcinoma. *Download PDF Copy ... ICC is a disease of significant unmet medical need and our Melphalan/HDS treatment may offer clinical benefit for ICC patients ...
Melphalan (US brand name Alkeran) is a chemotherapy drug commonly used to treat multiple myeloma. See common side effects and ... Melphalan (U.S. brand name Alkeran) is a chemotherapy drug commonly used in treating multiple myeloma. It belongs to the class ... In the U.S., melphalan is most commonly used in the treatment of MM as the conditioning agent in autologous stem cell ... As an oral agent given in combination therapy at lower doses, melphalan is well tolerated, and is often used to treat older, ...
Find the most comprehensive real-world treatment information on Melphalan-prednisone-thalidomide (MPT) at PatientsLikeMe. 14 ... bipolar I disorder or psoriasis currently take Melphalan-prednisone-thalidomide (MPT). ... See also: Melphalan Thalidomide Melphalan-prednisone-thalidomide, also known as MPT, is a regimen that may be used for the ... What is Melphalan-prednisone-thalidomide (MPT)?. Category: Prescription Drugs false ...
Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients ... Cost per QALY gained by the treatment with high-dose melphalan and autologous blood stem cell support was estimated at NOK ... Abstract: We evaluated the costs and the cost utility of high-dose melphalan and autologous stem cell support followed by ... Keywords: adult; antineoplastic agents; cost-benefit analysis; hematopoetic stem cell transplantation; melphalan; multiple ...
Injectable; Injection; Melphalan 50 mg*Tablets, Film-Coated; Oral; Melphalan 2 mg*Tablets, Film-Coated; Oral; Melphalan 5 mg. ...
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma. The safety and scientific validity of this study is the ... Drug Information available for: Thalidomide Melphalan Bortezomib Genetic and Rare Diseases Information Center resources: ... Melphalan. Thalidomide. BB 1101. Anti-Inflammatory Agents. Antiemetics. Autonomic Agents. Peripheral Nervous System Agents. ... The study is an open randomized multicentre study in which patients with multiple myeloma refractory to melphalan therapy are ...
Melphalan is leukemogenic in humans. Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should be ... Melphalan produces chromosomal aberrations in vitro and in vivo. Melphalan hydrochloride should be considered potentially ... Melphalan may lower your bodys resistance and the vaccine may not work as well or you might get the infection the vaccine is ... Melphalan can cause diarrhea, nausea or vomiting, or sores or ulcers in the mouth, sometimes even after you receive medicine to ...
Buy Melphalan Hydrochloride online at LGC Standards. High quality reference standards for the most reliable pharmaceutical ...
Experimental: Doxil® + Melphalan + Velcade (DMV) Drug: Doxil, melphalan, bortezomib Doxil®: IV over 30-60 min, Day 1 q28d ... Drug Information available for: Melphalan Melphalan hydrochloride Doxorubicin Doxorubicin hydrochloride Bortezomib Genetic and ... Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma (DMV). The safety and scientific validity of this ... Liposomal doxorubicin (Doxil), melphalan, and bortezomib all have different mechanisms of action and toxicity profiles. ...
  • Melphalan (trade name Alkeran , in former USSR also known as Sarcolysin ) is a chemotherapy drug belonging to the class of nitrogen mustard alkylating agents . (wikipedia.org)
  • Alkeran tablets and injection contain the active ingredient melphalan, which is a type of chemotherapy medicine to treat cancer called an alkylating agent. (netdoctor.co.uk)
  • ALKERAN (melphalan) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. (rxlist.com)
  • ALKERAN (melphalan) is available in tablet form for oral administration. (rxlist.com)
  • ALKERAN (melphalan) Tablets are indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary . (rxlist.com)
  • Because of the patient-to-patient variation in melphalan plasma levels following oral administration of the drug, several investigators have recommended that the dosage of ALKERAN (melphalan) be cautiously escalated until some myelosuppression is observed in order to assure that potentially therapeutic levels of the drug have been reached. (rxlist.com)
  • One study by Alexanian et al has shown that the use of ALKERAN (melphalan) in combination with prednisone significantly improves the percentage of patients with multiple myeloma who achieve palliation. (rxlist.com)
  • One regimen has been to administer courses of ALKERAN (melphalan) at 0.25 mg/kg/day for 4 consecutive days (or, 0.20 mg/kg/day for 5 consecutive days) for a total dose of 1 mg/kg/course. (rxlist.com)
  • Melphalan (U.S. brand name Alkeran) is a chemotherapy drug commonly used in treating multiple myeloma. (myeloma.org)
  • This multi-center trial will evaluate safety and efficacy in 60 patients, and is intended to confirm the results from an earlier Phase 2 study demonstrating that the Captisol-enabled melphalan formulation was safe and well-tolerated, and met the requirements for establishment of bioequivalence to the current commercial intravenous formulation of melphalan (sold by GlaxoSmithKline as Alkeran® for Injection). (fiercebiotech.com)
  • June 9 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC, announced today the FDA approval and launch of Melphalan Hydrochloride for Injection, the generic equivalent of Alkeran(R) from GlaxoSmithKline. (bio-medicine.org)
  • Captisol-enabled, PG-free melphalan, which has been granted Orphan designation by the FDA as a conditioning treatment for use in autologous transplant for patients with multiple myeloma, is a new IV formulation of melphalan (Alkeran for Injection). (empr.com)
  • Melphalan, sold under the trade name Alkeran among others, is a chemotherapy medication used to treat multiple myeloma, ovarian cancer, melanoma, and AL amyloidosis. (wikipedia.org)
  • Alkeran, also known by its scientific name melphalan, is a type of chemotherapy used in patients with certain cancers, including peritoneal mesothelioma. (mesotheliomahub.com)
  • A type of chemotherapy medication , Alkeran (melphalan), is also referred to as L-phenylalanine mustard, phenylalanine mustard, L-Pam, or L-sarcolysin. (mesotheliomahub.com)
  • Melphalan injection should be given only under the supervision of a doctor with experience in the use of chemotherapy medications. (medlineplus.gov)
  • In all instances where the use of Melphalan Hydrochloride for Injection is considered for chemotherapy, the physician must evaluate the need and usefulness of the drug against the risk of adverse events. (businesswire.com)
  • Melphalan Hydrochloride for Injection should be used with extreme caution in patients whose bone marrow reserve may have been compromised by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. (businesswire.com)
  • The use of the Captisol® technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy. (fiercebiotech.com)
  • This study aimed to investigate the safety and efficacy of intravitreal melphalan chemotherapy (IViC) as a treatment for recurrent and refractory vitreous seeds in patients with Rb. (frontiersin.org)
  • Herein, we have studied the use of intravitreous chemotherapy using single, standard lower-dose melphalan (20 µg/0.1 mL) for VS. (healio.com)
  • We studied the effect of long term melphalan-prednisolone (MP) therapy on six patients with POEMS syndrome, and compared the results with those for another six patients who did not receive this long term chemotherapy. (bmj.com)
  • Giving melphalan hydrochloride before a donor stem cell transplantation may work better than standard chemotherapy in helping to prevent multiple myeloma from coming back. (centerwatch.com)
  • Drugs used in chemotherapy, such as bendamustine hydrochloride and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (cancer.gov)
  • To improve the prognosis for patients with metastatic Ewing sarcoma/primitive neuroectodermal tumors (ES/PNET) using conventional chemotherapy and consolidation high-dose chemotherapy (HDCT) containing busulfan and melphalan. (ovid.com)
  • Because methylation of MGMT promoter increases the efficacy of alkylating agents, studies on melanoma outcome of patients treated with melphalan regional chemotherapy should consider this epigenetic change. (ovid.com)
  • This study aims to evaluate whether the survival of stage III melanoma patients treated with melphalan regional chemotherapy may be correlated with MGMT methylation status. (ovid.com)
  • We estimated an MGMT promoter methylation cut-off of at least 14%, which was significantly associated with a longer survival after melphalan regional chemotherapy. (ovid.com)
  • Our data suggest that MGMT promoter methylation could be an important factor in determining which melanoma patients should receive melphalan regional chemotherapy, but its prognostic significance in the routine clinical setting needs to be clarified in a larger study. (ovid.com)
  • Several in vitro studies indicate that melphalan flufenamide may be successfully combined with standard chemotherapy or targeted agents. (wikipedia.org)
  • Although m -L-sarcolysin never reached widespread clinical use, the well established para -isomer melphalan still, after nearly fifty years, has a place in cancer chemotherapy. (diva-portal.org)
  • MELPHALAN (MEL fa lan) is a chemotherapy drug. (va.gov)
  • The purpose of the study is to compare thalidomide + dexamethasone with bortezomib + dexamethasone in patients with multiple myeloma refractory to melphalan therapy. (clinicaltrials.gov)
  • The study is an open randomized multicentre study in which patients with multiple myeloma refractory to melphalan therapy are randomized between bortezomib and thalidomide therapy, in both arms with the addition of dexamethasone. (clinicaltrials.gov)
  • Liposomal doxorubicin (Doxil), melphalan, and bortezomib all have different mechanisms of action and toxicity profiles. (clinicaltrials.gov)
  • VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired. (nih.gov)
  • VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. (nih.gov)
  • PURPOSE To assess bortezomib plus melphalan and prednisone (VMP) and melphalan and prednisone (MP) in previously untreated patients with multiple myeloma (MM) with renal impairment enrolled on the phase III VISTA study, and to evaluate renal impairment reversibility. (nih.gov)
  • PATIENTS AND METHODS Patients received nine 6-week cycles of VMP (bortezomib 1.3 mg/m(2), melphalan 9 mg/m(2), prednisone 60 mg/m(2)) or MP. (nih.gov)
  • A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression. (knowcancer.com)
  • Investigators would like to explore all these three strategies in this study: Investigators propose to take patients who have had standard novel agent (bortezomib) based induction regimens into this study and then use a dose-adjusted combination of busulfan and melphalan as conditioning regimen and finally Investigators would like to incorporate lenalidomide maintenance post ASCT until disease progression. (knowcancer.com)
  • The goal of this clinical research study is to learn if the combination of Siltuximab (CNTO 328) and VMP (a combination of the drugs Velcade [bortezomib], melphalan, and prednisone) can more effectively control MM than VMP alone. (mdanderson.org)
  • To investigate the effects of these compounds on bortezomib's anti-proliferative potency and its intracellular accumulation and potency to inhibit the chymotrypsin-like proteasomal subunit, seven myeloma cell lines were investigated after exposure to bortezomib alone or either combined with adriamycin plus dexamethasone (PAD regimen) or melphalan plus prednisolone (VMP regimen), respectively. (springer.com)
  • This phase I/II trial studies the side effects and best dose of bortezomib when given together with melphalan, and total-body irradiation before stem cell transplant and to see how well it works in treating patients with multiple myeloma. (mayo.edu)
  • Bortezomib-melphalan-prednisone (VMP) is a standard-of-care for previously untreated, transplant-ineligible multiple myeloma (MM). (cun.es)
  • Clinical trials of alternate treatment options have tested non-transplant melphalan-based strategies and novel therapeutics such as lenalidomide and bortezomib. (haematologica.org)
  • We therefore compared autologous HSCT with bortezomib-melphalan-prednisone (VMP) as intensification therapy, and bortezomib-lenalidomide-dexamethasone (VRD) consolidation therapy with no consolidation. (eur.nl)
  • Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. (semanticscholar.org)
  • PURPOSE Bortezomib has shown synergy with melphalan in preclinical models. (semanticscholar.org)
  • Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). (semanticscholar.org)
  • Melphalan injection is used to treat multiple myeloma (a type of cancer of the bone marrow) in people who are unable to take melphalan by mouth. (medlineplus.gov)
  • Melphalan injection is also used to destroy bone marrow and cancer cells in preparation for a bone marrow transplant in people with multiple myeloma. (medlineplus.gov)
  • Melphalan injection comes as a powder to be mixed with liquid to be slowly injected intravenously (into a vein) over 15 to 30 minutes by a doctor or nurse in a medical facility. (medlineplus.gov)
  • When melphalan injection is given to treat multiple myleoma in people who are unable to take melphalan by mouth, it is usually given once every 2 weeks for 4 doses and afterwards, once every 4 weeks for as long as your doctor recommends that you receive treatment. (medlineplus.gov)
  • Melphalan injection may cause nausea and vomiting during treatment with the medication. (medlineplus.gov)
  • Your doctor may not want you to receive melphalan injection. (medlineplus.gov)
  • Melphalan injection may cause side effects. (medlineplus.gov)
  • Melphalan hydrochloride for injection is supplied as a sterile, nonpyrogenic, freeze-dried powder. (nih.gov)
  • Melphalan hydrochloride for injection is reconstituted using the sterile diluent provided. (nih.gov)
  • Melphalan hydrochloride for Injection is supplied as a sterile, nonpyrogenic, white to off white lyophilized cake or powder. (nih.gov)
  • Melphalan may be taken either orally in pill form or as an injection in liquid form. (encyclopedia.com)
  • Call your doctor for instructions if you miss an appointment for your melphalan injection. (rexhealth.com)
  • LAKE ZURICH, Ill.--( BUSINESS WIRE )--Fresenius Kabi announced today the immediate availability in the United States of Melphalan Hydrochloride for Injection. (businesswire.com)
  • Fresenius Kabi Melphalan Hydrochloride for Injection is available as a two-vial kit containing one single dose vial of Melphalan Hydrochloride equivalent to 50 mg Melphalan and one vial of sterile diluent. (businesswire.com)
  • Melphalan Hydrochloride for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. (businesswire.com)
  • Melphalan Hydrochloride for Injection should not be used in patients whose disease has demonstrated prior resistance to this agent. (businesswire.com)
  • Melphalan Hydrochloride for Injection may cause local tissue damage should extravasation occur, and consequently it should not be administered by direct injection into a peripheral vein. (businesswire.com)
  • It is recommended that Melphalan Hydrochloride be administered by injecting slowly into a fast-running IV infusion via an injection port, or via a central venous line. (businesswire.com)
  • This important safety information does not include all the information needed to use MELPHALAN HYDROCHLORIDE FOR INJECTION safely and effectively. (businesswire.com)
  • Melphalan injection should only be used to treat people who are unable to take melphalan by mouth. (epnet.com)
  • Melphalan injection is used to treat multiple myeloma (bone marrow cancer) and as a conditioning treatment before a bone marrow transplantation procedure in patients with multiple myeloma. (allinahealth.org)
  • Appropriate studies have not been performed on the relationship of age to the effects of melphalan injection in the pediatric population. (allinahealth.org)
  • Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of melphalan injection in the elderly. (allinahealth.org)
  • Melphalan injection is used as a "conditioning" treatment for multiple myeloma before you receive a stem cell transplant. (caldwellmemorial.org)
  • Melphalan injection is given as an infusion through a central intravenous (IV) line placed into a large vein. (caldwellmemorial.org)
  • Melphalan injection is usually given every 2 to 4 weeks. (caldwellmemorial.org)
  • Melphalan injection is usually given for 2 days in a row before stem cell transplant. (caldwellmemorial.org)
  • Bioniche Pharma will commence shipment of Melphalan Hydrochloride for Injection immediately in cartons with one single-use vial containing melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL vial of sterile diluent. (bio-medicine.org)
  • I. To determine the optimal dose and schedule of melphalan for injection (melphalan hydrochloride [Evomela]) prior to autologous hematopoietic stem cell transplantation (auto-HCT) for multiple myeloma (MM). (centerwatch.com)
  • Evomela (melphalan) for Injection, for Intravenous Use. (wikipedia.org)
  • In rat, melphalan in isolated lung perfusion (ILP) functions as a potent therapeutics for sarcomatous pulmonary metastases. (sigmaaldrich.com)
  • Boschmans J, De Bruijn E, Van Schil P, Lemiere F (2013) Analysis of novel melphalan hydrolysis products formed under isolated lung perfusion conditions using liquid chromatography/tandem mass spectrometry. (springer.com)
  • A randomized trial compared prednisone plus IV melphalan to prednisone plus oral melphalan in the treatment of myeloma. (nih.gov)
  • What is Melphalan-prednisone-thalidomide (MPT)? (patientslikeme.com)
  • Melphalan-prednisone-thalidomide, also known as MPT, is a regimen that may be used for the treatment of multiple myeloma. (patientslikeme.com)
  • It contains the anticancer agents melphalan and thalidomide along with prednisone, a corticosteroid. (patientslikeme.com)
  • There are no evaluations for Melphalan-prednisone-thalidomide (MPT). (patientslikeme.com)
  • Abstract: We evaluated the costs and the cost utility of high-dose melphalan and autologous stem cell support followed by interferon maintenance relative to conventional treatment with melphalan and prednisone, in patients less than 60 yr of age with multiple myeloma. (ingentaconnect.com)
  • In Multiple Myeloma patients, the standard treatment is the oral combination of Melphalan and Prednisone (MP). (bioportfolio.com)
  • This study will evaluate the safety and efficacy of the association of Melphalan/Prednisone/Revlimid (MPR) as induction treatment for newly diagnosed myeloma patients over age 65 or those under 65 years who refuse or are not eligible for high dose therapy. (bioportfolio.com)
  • In the first part of the study (phase I component), different doses of oral Melphalan (0.18-0.25 mg/Kg) associated with Prednisone (MP) will be combined with escalating doses of Revlimid (from 5 mg/day) and administered together. (bioportfolio.com)
  • This study will determine whether the association of Revlimid and Prednisone (RP) as induction treatment followed by Revlimid, Melphalan and Prednisone (MPR) as consolidation treatment is. (bioportfolio.com)
  • Primary Objective In subjects with previously untreated multiple myeloma, the primary objectives of the study are: Part 1 To assess the safety of CNTO 328 at a dose of 11 mg/kg every 3 weeks when administered in combination with Velcade, melphalan, and prednisone (VMP). (mdanderson.org)
  • Don t know/doesn t apply prednisone melphalan larger than normal sex-drive be sure of the active jaw. (bigsurlandtrust.org)
  • Patients ineligible for ASCT are usually treated with standard oral melphalan and prednisone, but the response rate to this regimen is unsatisfactory, and time to response is long. (bloodjournal.org)
  • Patients ineligible for ASCT are usually treated with standard oral melphalan and prednisone. (bloodjournal.org)
  • To evaluate the addition of low-dose interferon-α2b to standard melphalan-prednisone therapy in patients with multiple myeloma. (annals.org)
  • All patients received melphalan-prednisone every 6 weeks. (annals.org)
  • Melphalan-prednisone therapy was interrupted after at least 8 courses in responding patients who achieved a plateau phase, and it was reinstituted at time of relapse. (annals.org)
  • Patients randomly assigned to receive melphalan-prednisone and interferon also received interferon, 5 MU three times weekly, from the start of treatment through response, plateau phase, and relapse, until definitive failure of melphalan-prednisone occurred. (annals.org)
  • 45% of patients receiving melphalan-prednisone and 44% of patients receiving melphalan-prednisone and interferon achieved at least a partial response. (annals.org)
  • Toxicity was higher with melphalan-prednisone and interferon, and this led to premature discontinuation of interferon therapy in one third of patients and to a reduced overall dose intensity for melphalan. (annals.org)
  • The median survival time was 29 months for patients receiving melphalan-prednisone and 32 months for patients receiving melphalan-prednisone and interferon. (annals.org)
  • The risk ratio for death for patients receiving melphalan-prednisone compared with patients receiving melphalan-prednisone and interferon was 1.02 (95% CI, 0.89 to 1.40). (annals.org)
  • Adding continuous low-dose interferon to standard melphalan-prednisone therapy does not improve response rate or survival. (annals.org)
  • In patients younger than 65 newly diagnosed with myeloma, high-dose melphalan plus autologous SCT improved progression-free survival and overall survival compared with melphalan/prednisone/lenalidomide consolidation. (ascopost.com)
  • In a phase III trial reported in The New England Journal of Medicine , Palumbo et al found that consolidation therapy with high-dose melphalan plus autologous stem cell transplantation improved progression-free survival and overall survival compared with melphalan/prednisone/lenalidomide (Revlimid) consolidation and that lenalidomide maintenance vs no maintenance improved progression-free survival in patients ≤ 65 years newly diagnosed with multiple myeloma. (ascopost.com)
  • In this open-label trial, 273 patients aged ≤ 65 years with newly diagnosed multiple myeloma from 62 centers in Israel and Italy were randomly assigned between November 2007 and July 2009 to receive high-dose melphalan (200 mg/m 2 ) followed by autologous stem cell transplantation (n = 141) or melphalan/prednisone/lenalidomide consolidation (n = 132) after induction therapy with lenalidomide and dexamethasone. (ascopost.com)
  • Of these, a total of 251 were further randomly assigned to lenalidomide maintenance after high-dose melphalan consolidation (n = 67) or melphalan/prednisone/lenalidomide consolidation (n = 59), or no lenalidomide maintenance after high-dose melphalan (n = 68) or melphalan/prednisone/lenalidomide (n = 57). (ascopost.com)
  • Median progression-free survival from time of diagnosis was 54.7 months in patients who received high-dose melphalan plus lenalidomide maintenance, 37.4 months in those receiving high-dose melphalan without maintenance, 34.2 months in those receiving melphalan/prednisone/lenalidomide plus lenalidomide maintenance, and 21.8 months in those receiving melphalan/prednisone/lenalidomide without maintenance. (ascopost.com)
  • Treatment was discontinued due to adverse events in 4% of patients during induction and in 0.7% during high-dose melphalan treatment and 3.0% during melphalan/prednisone/lenalidomide treatment. (ascopost.com)
  • Second primary cancers were observed in 0.3% of patients during induction, in no patients during high-dose melphalan or melphalan/prednisone/lenalidomide consolidation, and in 4.3% of both the lenalidomide maintenance and no maintenance groups during the maintenance period. (ascopost.com)
  • The investigators concluded: "[W]e found that consolidation therapy with high-dose melphalan, as compared with melphalan/prednisone/lenalidomide, improved progression-free and overall survival, although at a cost of increased toxicity. (ascopost.com)
  • Standard first-line treatment for elderly multiple myeloma (MM) patients ineligible for stem cell transplantation is melphalan plus prednisone (MP). (cun.es)
  • The current standard of care for elderly MM patients includes the nitrogen mustard alkylating agent melphalan in conjunction with prednisone. (biomedcentral.com)
  • Melphalan can cause a severe decrease in the number of blood cells in your bone marrow. (medlineplus.gov)
  • Melphalan is used to treat multiple myeloma (a type of cancer of the bone marrow). (medlineplus.gov)
  • Melphalan is mainly used in the treatment of bone marrow cancer (multiple myeloma), but may also sometimes be used to treat advanced cancer of the ovaries or skin cancer. (netdoctor.co.uk)
  • When melphalan is given to people with multiple myeloma to destroy bone marrow and cancer cells in preparation for a bone marrow transplant, it is usually injected once a day for 2 days before bone marrow transplant. (medlineplus.gov)
  • Melphalan acts as a bone-marrow depressant and is implicated in the treatment of multiple myeloma and ovarian cancer. (sigmaaldrich.com)
  • Giving fludarabine phosphate, melphalan, and IMTMI before a donor stem cell transplant may help stop the growth of cells in the bone marrow, including normal blood-forming cells ( stem cells ) and cancer cells. (aamds.org)
  • NOTE: *Patients with gliomas localized to the posterior circulation (i.e., brain stem gliomas) receive melphalan on day 1 only. (knowcancer.com)
  • GROUP 1: Participants receive melphalan hydrochloride intravenously (IV) over 30-60 minutes on day -2. (centerwatch.com)
  • GROUP 2: Participants receive melphalan hydrochloride IV over 8-9 hours on day -2. (centerwatch.com)
  • In the U.S., melphalan is most commonly used in the treatment of MM as the conditioning agent in autologous stem cell transplant. (myeloma.org)
  • The Captisol-enabled melphalan program is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. (fiercebiotech.com)
  • This phase I trial investigates the side effects of bendamustine hydrochloride and melphalan in treating elderly patients with multiple myeloma or B-cell Lymphoma that has come back (relapsed) or does not respond to treatment (refractory) before undergoing stem cell transplant. (cancer.gov)
  • This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood (hematologic) that have returned after a period of improvement (relapsed) undergoing a second donor stem cell transplant. (aamds.org)
  • 1 - 3 High-dose melphalan with autologous stem cell transplant (HDM/SCT) is an effective treatment with high complete hematologic response rates (CR) and is capable of producing durable remissions and prolonged overall survival. (haematologica.org)
  • Mean (±SD) peak melphalan plasma concentrations in myeloma patients given IV melphalan at doses of 10 or 20 mg/m 2 were 1.2 ± 0.4 and 2.8 ± 1.9 mcg/mL, respectively. (nih.gov)
  • Melphalan has been used as a drug along with HDAC-inhibitor JNJ-26481585 to treat multiple myeloma (MM) in cell lines and as a chemotherapeutic agent for breast cancer cell line. (sigmaaldrich.com)
  • Melphalan treats only the symptoms of ovarian cancer or multiple myeloma, but does not treat the cancer itself. (rexhealth.com)
  • From March 1994 to July 1997, 274 patients with newly diagnosed, symptomatic multiple myeloma were enrolled in a prospective, non-randomized, population-based, multicenter study to evaluate the treatment with high-dose melphalan and autologous blood stem cell support. (ingentaconnect.com)
  • Melphalan is FDA approved to treat people who have myeloma. (schoolandyouth.org)
  • Ligand's Captisol-enabled, PG-free melphalan program is a new intravenous formulation of melphalan being investigated for the multiple myeloma transplant setting, and has been granted Orphan designation by the FDA. (fiercebiotech.com)
  • 4) Conclusions: Decitabine and melphalan does not appear as a promising combination for inducing p73 and bypassing p53 deficiency in myeloma cells. (mdpi.com)
  • Melphalan is used as a "palliative" treatment to relieve symptoms of multiple myeloma (a type of blood cancer) or a certain type of ovarian cancer. (caldwellmemorial.org)
  • This phase I/II trial studies the side effects and best dose of melphalan hydrochloride in treating participants with newly-diagnosed multiple myeloma who are undergoing a donor stem cell transplantation. (centerwatch.com)
  • I. To establish day +30 safety and toxicity of the combination conditioning regimen of bendamustine hydrochloride (bendamustine) and melphalan followed by reinfusion of autologous stem cell in elderly patients with multiple myeloma (MM) or B-cell non-Hodgkin lymphoma (NHL). (cancer.gov)
  • Analyze the results of ASCT using intravenous Busulfan and Melphalan as conditioning regimen for patients with Multiple Myeloma. (centerwatch.com)
  • These data show impressive synergistic action of the novel HSP90 inhibitor NVP-AUY922 with melphalan, doxorubicin, NVP-LBH589, and SAHA in multiple myeloma and build the frame work for clinical trials. (nih.gov)
  • Nath CE, Trotman J, Tiley C et al (2016) High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. (springer.com)
  • Our findings confirm that high-dose melphalan remains the more effective therapeutic option in patients with newly diagnosed multiple myeloma. (ascopost.com)
  • Ligand Pharmaceuticals announced results from a Phase 2 study of Captisol-enabled, propylene glycol-free (PG-free) melphalan in multiple myeloma patients undergoing autologous transplantation. (empr.com)
  • In 2016, it was approved in the U.S. for: use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in multiple myeloma (MM) patients the palliative treatment of MM patients for whom oral therapy is not appropriate Melphalan is currently[when? (wikipedia.org)
  • Melphalan flufenamide, sold under the brand name Pepaxto, is an anticancer medication used to treat multiple myeloma. (wikipedia.org)
  • Melphalan flufenamide is indicated in combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma, with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody. (wikipedia.org)
  • A preclinical study, performed at Dana-Farber Cancer Institute, demonstrated that melphalan flufenamide induced apoptosis in multiple myeloma cell lines, even those resistant to conventional treatment (including melphalan). (wikipedia.org)
  • High dose melphalan 200mg/m2 (MEL200) followed by autologous stem cell transplantation (ASCT) is the standard of care for fit patients with Multiple Myeloma (MM). Bendamustine has been shown to induce responses in MM resistant to other alkylating agents. (confex.com)
  • To determine the efficacy of targeted radiotherapy delivered by an Yttrium-90 (90Y)-radio-labelled murine anti-CD66 monoclonal antibody, given in addition to high dose melphalan (200 mg/m^2) in terms of disease response (complete remission rate and change of serum free light chain level pre and post yttrium-90-radio-labelled anti-CD66) in patients undergoing haematopoietic stem cell transplantation (HSCT) for multiple myeloma. (isrctn.com)
  • It is hypothesized that melflufen could provide better efficacy but no more toxicity than what is achieved with melphalan, an assumption so far supported by experiences from hollow fiber and xenograft studies in rodents as well as by clinical data from patients with solid tumors and multiple myeloma. (semanticscholar.org)
  • Melphalan is a medication in the alkylater class used as a tablet to treat cancer of the breast and ovary, sarcoma, melanoma, multiple myeloma and polycythaemia vera. (afairgo.net)
  • Melflufen triggers a rapid, robust, and an irreversible DNA damage which may account for its ability to overcome melphalan-resistance in multiple myeloma cells. (ncats.io)
  • The activity of J1 ( l -melphalanyl- p - l -fluorophenylalanine ethyl ester), an enzymatically activated melphalan prodrug, was evaluated in neuroblastoma models in vitro and in vivo . (aacrjournals.org)
  • In conclusion, the melphalan prodrug J1 is highly active in models of neuroblastoma in vitro and in vivo , encouraging further clinical development in this patient group. (aacrjournals.org)
  • In this work, we designed a new ROS-responsive prodrug by using Melphalan (MPH) covalently coupled with methoxy polyethylene glycol (mPEG) through a ROS-cleavable group thioketal (TK), demonstrating the capacity to self-assembly into nanosized micelles. (inserm.fr)
  • The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. (semanticscholar.org)
  • A role of APN in the activation of the melphalan prodrug J1 and subsequently, its cytotoxic effects is demonstrated and data suggest that J1 may be activated in a tumor selective manner. (semanticscholar.org)
  • Melphalan flufenamide ethyl ester (melflufen, previously denoted J1) is a peptidase-potentiated dipeptide prodrug of alkylating agent melphalan. (ncats.io)
  • What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone? (nature.com)
  • This study compared the responses to and survival of 347 POEMS syndrome patients given three first-line treatment regimens: autologous stem cell transplantation (ASCT, N = 165) and melphalan + dexamethasone (MDex, N = 79), or lenalidomide + dexamethasone (LDex, N = 103). (nature.com)
  • Mizuno K, Dong M, Fukuda T et al (2018) Population pharmacokinetics and optimal sampling strategy for model-based precision dosing of melphalan in patients undergoing hematopoietic stem cell transplantation. (springer.com)
  • To find out the safety and tolerability of reduced intensity conditioning (RIC) consisting of Propyhlene Glycol-Free Melphalan HCI (EVOMELA) in combination with Fludarabine and Total Body Irradiation (TBI) for subjects undergoing Haplo Identical (which involves matching your tissue type with a related or unrelated donor) Hematopoietic Cell Transplantation (Haplo-HCT). (froedtert.com)
  • Two weeks later patients will receive the standard pre-conditioning regimen of high dose melphalan (200 mg/m^2) prior to autologous stem cell transplantation. (isrctn.com)
  • There are no common side effects of melphalan. (encyclopedia.com)
  • Determine the toxic effects of melphalan given with BBBD in these patients. (knowcancer.com)
  • Hypersensitivity reactions, including anaphylaxis, have occurred in patients who received the IV formulation of melphalan hydrochloride. (allinahealth.org)
  • Cost per QALY gained by the treatment with high-dose melphalan and autologous blood stem cell support was estimated at NOK 249,000 (USD 27,000). (ingentaconnect.com)
  • The Company recently announced the expansion of its global Phase 2 clinical study in primary liver cancer (HCC) to include an ICC cohort, which is investigating the safety and efficacy of Melphalan/HDS treatment in patients with unresectable ICC confined to the liver. (news-medical.net)
  • Thus, the investigators are initiating a phase I/II study to examine the safety and efficacy of combining all three agents into the regimen DMV (Doxil® + melphalan + Velcade). (clinicaltrials.gov)
  • The major cause of failure in the management of retinoblastoma is the persistence/recurrence of vitreous seeds (VS). This study reports the efficacy and complications of standard lower-dose (20 µg) intravitreal melphalan for VS. (healio.com)
  • In an effort to improve efficacy while maintaining tolerability, the opportunity for synergy is raised with melphalan and lenalidomide in combination with dexamethasone. (haematologica.org)
  • To determine whether a novel NF-κB inhibitor, KZ-41, can inhibit melphalan's actions on retinal endothelial cells (REC) inflammation and apoptosis, without eliminating the chemotherapeutic efficacy of melphalan on cell death of retinoblastoma cells (Y79). (arvojournals.org)
  • Melphalan is currently being used to treat ocular retinoblastoma , a pediatric solid tumor. (wikipedia.org)
  • 112 patients were treated by isolated limb perfusion with tumor necrosis factor (TNF) and melphalan for locoregional metastases of melanoma (49 patients) or locally advanced soft tissue sarcoma (63 patients). (hu-berlin.de)
  • Athymic rats and mice carrying neuroblastoma xenografts [SH-SY5Y, SK-N-BE(2)] were treated with equimolar doses of melphalan, J1, or no drug, and effects on tumor growth and tissue morphology were analyzed. (aacrjournals.org)
  • Compared with melphalan, J1 more effectively inhibited the growth of mice with SH-SY5Y xenografts, was associated with higher caspase-3 activation, fewer proliferating tumor cells, and significantly decreased mean vascular density. (aacrjournals.org)
  • medical citation needed] Melphalan flufenamide is a peptidase enhanced cytotoxic (PEnC) with a targeted delivery within tumor cells of melphalan, a widely used classical chemotherapeutic belonging to a group of alkylating agents developed more than 50 years ago. (wikipedia.org)
  • Melphalan flufenamide was synthesized, partly due to previous experience of an alkylating peptide cocktail named Peptichemio and its anti-tumor activity is being investigated. (wikipedia.org)
  • Out of 100 tumor necrosis factor (TNF)-based ILPs with TNF and melphalan (TM-ILPs) in melanoma patients between March 1991 and July 2003, 25 repeat ILP procedures were performed in 21 patients in whom prior ILP treatment failed. (eur.nl)
  • Controlled trials comparing intravenous (IV) to oral melphalan have shown more myelosuppression with the IV formulation. (nih.gov)
  • Arm 1: Oral melphalan 0.15 mg/kg/day x 7 followed by 0.05 mg/kg/day when WBC began to rise. (nih.gov)
  • Oral melphalan is a tablet you take by mouth. (rexhealth.com)
  • We evaluated the combination of oral melphalan and high-dose dexamethasone (M-Dex) in 46 patients with AL ineligible for ASCT. (bloodjournal.org)
  • A reliable factor to predict adequate yields was prior therapy: an adequate collection was obtained in 92% of patients treated with conventional non-alkylating therapy (VAD-based regimens), in 56% treated with oral melphalan and in 23% who had received intravenous melphalan. (haematologica.org)
  • CI=0.01-0.61), when compared to the group treated with oral melphalan. (haematologica.org)
  • Oral melphalan was administered in escalating doses from 0.025 to 0.25 mg/kg on days 1 to 4. (semanticscholar.org)
  • OUTLINE: This is a dose-escalation study of melphalan. (knowcancer.com)
  • OUTLINE: This is a phase I, dose escalation study of melphalan hydrochloride followed by a phase II study. (centerwatch.com)
  • Another amino acid -like drug is the antineoplastic agent melphalan. (wikipedia.org)
  • If you have an allergy to melphalan or any other part of this drug. (mskcc.org)
  • Patients with a prior allergic reaction to melphalan should not take the drug. (encyclopedia.com)
  • Melphalan can cause serious birth defects if either the man or the woman is taking this drug at the time of conception, or if the woman is taking this drug during pregnancy. (encyclopedia.com)
  • Because melphalan is such a potent immunosuppressant, patients taking this drug must exercise extreme caution to avoid contracting any new infections. (encyclopedia.com)
  • Melphalan should not be taken in combination with any prescription drug, over-the-counter drug, or herbal remedy without prior consultation with a physician. (encyclopedia.com)
  • Patients who have demonstrated hypersensitivity to melphalan should not be given the drug. (businesswire.com)
  • Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma. (news-medical.net)
  • We are pleased with the receipt of orphan drug designation for melphalan in the treatment of patients with cholangiocarcinoma as it is a key milestone that supports our broader regulatory and development strategy for our Melphalan/Hepatic Delivery System (Melphalan/HDS) as a therapy for primary and metastatic liver cancers,' said Jennifer Simpson, Ph.D., M.S.N., C.R.N.P., President and Chief Executive Officer of Delcath. (news-medical.net)
  • This Treatment Guide contains information about Melphalan, a drug used in the treatment of AL amyloidosis. (myeloma.org.uk)
  • Bioniche Pharma and Synerx Pharma entered into a definitive agreement whereby Synerx developed and secured the U.S. Food and Drug Administration's approval of Melphalan and Bioniche Pharma has the exclusive rights to market and distribute Melphalan in the United States. (bio-medicine.org)
  • The alkylating drug melphalan is routinely used in high-dose protocols for children with advanced neuroblastoma. (aacrjournals.org)
  • As a result of a screening of peptides, based on pharmacologic data on Peptichemio and melphalan, a highly effective drug candidate, J1 ( l -melphalanyl- p - l -fluorophenylalanine ethyl ester), exhibiting higher in vitro and in vivo cytotoxicity than melphalan, was synthesized ( 6 - 8 ). (aacrjournals.org)
  • There is a need for novel therapies able to bypass drug resistance of high-risk neuroblastoma, and based on previous experience with melphalan and Peptichemio in this diagnosis, it seemed adequate to investigate if J1 is active as a single agent or in combination with standard drugs in experimental models of neuroblastoma in vitro and in vivo . (aacrjournals.org)
  • This is not a complete list of melphalan drug interactions. (rxwiki.com)
  • The drug usually used before transplant is melphalan alone in 1 or 2 high doses. (clinicalconnection.com)
  • Chemically, the drug is best described as the ethyl ester of a dipeptide consisting of melphalan and the amino acid derivative para-fluoro-L-phenylalanine. (wikipedia.org)
  • Melphalan is a type of anti-cancer drug that's classified as an alkylating agent. (mesotheliomahub.com)
  • Heating in acid with oxirane , followed by treatment with phosphorus oxychloride provided the bischloride, and removal of the protecting groups by heating in hydrochloric acid gave melphalan ( 3 ). (wikipedia.org)
  • Your doctor may need to delay your treatment or adjust your dose of melphalan depending on your response to treatment and any side effects that you experience. (medlineplus.gov)
  • Long-term treatment with melphalan may increase the risk of developing leukaemia (cancer of the white blood cells) after many years. (netdoctor.co.uk)
  • You should not use melphalan if you are allergic to it, or if prior treatment with this medication was unsuccessful in controlling your disease. (rexhealth.com)
  • Use effective birth control to avoid pregnancy during your treatment with melphalan. (rexhealth.com)
  • The following information on adverse reactions is based on data from both oral and IV administration of Melphalan Hydrochloride as a single agent, using several different dose schedules for treatment of a wide variety of malignancies. (businesswire.com)
  • ICC is a disease of significant unmet medical need and our Melphalan/HDS treatment may offer clinical benefit for ICC patients who face limited treatment options. (news-medical.net)
  • Discontinue treatment with melphalan hydrochloride for serious hypersensitivity reactions. (allinahealth.org)
  • Before you begin treatment with melphalan, talk to your doctor about the benefits as well as the risks of using it. (allinahealth.org)
  • Patients received lenalidomide 10 mg/day orally on days 1-21, melphalan 0.18 mg/kg orally on days 1-4, and dexamethasone 40 mg orally once weekly of a 28-day cycle (MDR treatment). (clinicaltrials.gov)
  • IViC with melphalan is effective (more for focal than diffuse seeding) and a relatively safe treatment modality for Rb that can improve the outcomes of eye salvage procedures. (frontiersin.org)
  • We studied the use of melphalan 180 mg/m2 followed by allogeneic peripheral blood stem cells (PBSC) as salvage treatment for patients relapsing after related (n = 7) or matched unrelated transplants (n = 3). (unboundmedicine.com)
  • Treatment protocol consisted of melphalan 5 mg/m 2 /day for four days, lenalidomide 10 mg/day for 21 days and dexamethasone 20-40 mg once a week every 28 days for a total of 12 cycles. (haematologica.org)
  • When metastases are located in the pelvis, melphalan hypoxic perfusion can be an optional treatment. (ovid.com)
  • Once cells reached confluence, they were treated with or without 10 μM KZ-41, following treatment with 4 μg/ml melphalan. (arvojournals.org)
  • REC were also transfected with or without NF-κB siRNA before melphalan treatment to determine the involvement of NF-κB in REC apoptosis and ICAM-1 levels. (arvojournals.org)
  • Phospho-P38MAPK inhibitor was also treated before KZ-41 and melphalan treatment and cell lysates were tested for ICAM-1 levels and REC cell death. (arvojournals.org)
  • We also cultured retinoblastoma cells (Y79) in RMPI-1640 medium supplemented with 20% fetal bovine serum and antibiotics and performed a cell death ELISA after melphalan + KZ-41 treatment to verify that the treatments did not alter melphalan's ability to promote cell death of Y79 cells. (arvojournals.org)
  • Knocking down APE1 sensitizes the melphalan resistant MM cells to melphalan treatment. (biomedcentral.com)
  • To determine the toxicity of busulfan and melphalan when used as a high-dose conditioning therapy for ASCT. (knowcancer.com)
  • To determine the toxicity of lenalidomide maintenance post busulfan and melphalan conditioning ASCT. (knowcancer.com)
  • AG (180 mg/m 2 ) plus melphalan (the dose lethal to 10% of animals) produced greater weight loss compared with melphalan alone, whereas DDC plus melphalan produced no additional toxicity. (springer.com)
  • PG-free melphalan, administered as half of a high-dose conditioning regimen, resulted in successful myeloablation (100% of patients) and subsequent engraftment (100% of patients) with no additional toxicity. (empr.com)
  • Finally, the in vivo toxicity and activity of melphalan and J3 were investigated in mice bearing human leukemia cells in s.c. fibers. (diva-portal.org)
  • Nath CE, Shaw PJ, Montgomery K, Earl JW (2007) Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. (springer.com)
  • In this study, researchers want to find out if using the VTD regimen, along with higher doses melphalan, in subjects who have relapsed or progressed after previous transplant(s), can be given safely to subjects who have failed previous transplant(s). (clinicalconnection.com)
  • Otherwise known as L -phenylalanine mustard, or L -PAM, melphalan is a phenylalanine derivative of chlormethine . (wikipedia.org)
  • Melphalan also known as L-phenylalanine mustard is an alkylating agent. (sigmaaldrich.com)
  • Melphalan is a nitrogen mustard derivative and belongs to the group of alkylating anticancer agents. (encyclopedia.com)
  • Melphalan belongs to the class of nitrogen mustard alkylating agents. (wikipedia.org)
  • Melphalan flufenamide is metabolized by aminopeptidase hydrolysis and by spontaneous hydrolysis on N-mustard. (wikipedia.org)
  • In December 2012 Ligand announced the initiation of a pivotal trial of Captisol-enabled melphalan. (fiercebiotech.com)
  • tell your doctor and pharmacist if you are allergic to melphalan, any other medications, or any of the ingredients in melphalan tablets. (medlineplus.gov)
  • Store melphalan tablets in the refrigerator and protect them from light. (rexhealth.com)
  • We here present an update of our single-center experience with fludarabine-melphalan as a preparative regimen. (haematologica.org)
  • Patients in complete or very good partial remission received HDCT with busulfan total dose 600 mg/m2 and melphalan 140 mg/m2 followed by autologous blood stem cells. (ovid.com)
  • Melphalan can be used alone, or in combination with other anti-cancer medicines or surgery. (netdoctor.co.uk)
  • As an oral agent given in combination therapy at lower doses, melphalan is well tolerated, and is often used to treat older, frail patients. (myeloma.org)
  • Determine the maximum tolerated dose of intra-arterial melphalan when given in combination with BBBD in patients with primary or metastatic CNS malignancy. (knowcancer.com)
  • This is the first study showing that J1 effectively inhibits neuroblastoma cell growth in vitro and in vivo by the induction of apoptosis, being significantly more effective than melphalan and with additive or synergistic effects in combination with cytotoxic drugs routinely used for children with advanced neuroblastoma. (aacrjournals.org)
  • Cohorts of 3-6 patients receive escalating doses of melphalan until the maximum tolerated dose (MTD) is determined. (knowcancer.com)
  • J1 is rapidly incorporated into the cytoplasm followed by intracellular hydrolysis, which results in the release of melphalan. (aacrjournals.org)
  • AG (90 mg/m 2 ) enhanced the activity of melphalan against TE-671, with growth delays increasing by 8.4, 15.8, and 21.2 days over the regimen with melphalan only. (springer.com)
  • Melphalan can cause an allergic reaction in some people. (encyclopedia.com)
  • You should not use melphalan if you are allergic to it, or if you received this medicine in the past and it did not work. (caldwellmemorial.org)
  • PEPAXTO is contraindicated in patients with a history of serious allergic reaction to melphalan flufenamide or melphalan. (onclive.com)
  • Melphalan chemically alters the DNA nucleotide guanine through alkylation , and causes linkages between strands of DNA. (wikipedia.org)
  • Melphalan is a highly effective alkylating agent which causes many types of DNA lesions, including DNA base alkylation damage that is repaired by base excision repair (BER). (biomedcentral.com)
  • Melphalan hydrochloride is administered intravenously. (nih.gov)
  • The melphalan dose was 90 mg/m2 intravenously on days -4 and -3 with PBSC infusion on day 0. (unboundmedicine.com)
  • Melphalan flufenamide is a peptidase enhanced cytotoxic (PEnC) that exerts a targeted delivery of melphalan in cells with high expression of aminopeptidases, such as aminopeptidase N, which has been described as over-expressed in human malignancies. (wikipedia.org)
  • medical citation needed] Melphalan flufenamide was approved for medical use in the United States in February 2021. (wikipedia.org)
  • Compared to melphalan, melphalan flufenamide exhibits significantly higher in vitro and in vivo activity in several models of human cancer. (wikipedia.org)
  • concentrations generally exceeded those of melphalan flufenamide during ongoing infusion. (wikipedia.org)
  • Melphalan flufenamide rapidly disappeared from plasma after infusion, while melphalan typically peaked a few minutes after the end of infusion. (wikipedia.org)
  • This suggests that melphalan flufenamide is rapidly and widely distributed to extravasal tissues, in which melphalan is formed and thereafter redistributed to plasma. (wikipedia.org)
  • Nonclinical safety studies with melphalan flufenamide at dosages exceeding the recommended dose for PEPAXTO were associated with mortality. (onclive.com)
  • There is no information regarding the presence of melphalan flufenamide or its metabolites in human breast milk, or the effects on the breastfed child or on milk production. (onclive.com)
  • This study demonstrates through all methods used, that melphalan-flufenamide besides being an alkylating agent also reveals anti-angiogenic effects in different preclinical models in vitro and in vivo. (semanticscholar.org)
  • Melphalan is also used to treat a certain type of ovarian cancer (cancer that begins in the female reproductive organs where eggs are formed). (medlineplus.gov)
  • Melphalan belongs to a group of drugs called alkylating agents. (rxwiki.com)
  • Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should be considered potentially mutagenic in humans. (nih.gov)
  • Melphalan produces chromosomal aberrations in vitro and in vivo. (allinahealth.org)
  • It was speculated that the increased activity compared to melphalan itself, demonstrated both in vitro and in vivo, resided in increased transport over the tumour cell membrane and/or hydrolytic cleavage and liberation of melphalan inside the cells. (semanticscholar.org)
  • The metastatic tissues of 27 stage III melanoma patients with locoregional metastases located in the pelvis subjected to melphalan hypoxic pelvic perfusion were examined. (ovid.com)
  • Human melanoma targeting with alpha-MSH-melphalan conjugate. (ac.be)
  • The current intravenous melphalan market is approximately $130 million annually, with predominant use in stem cell transplants. (fiercebiotech.com)
  • Retrospective review of all patients with active VS treated with lower-dose intravitreal melphalan (20 µg/0.1 mL) on a monthly basis until complete VS regression was achieved. (healio.com)
  • The 2-year results of this study suggest that standard lower-dose (20 µg) intravitreal melphalan is safe and highly effective for the management of viable VS from retinoblastoma. (healio.com)
  • Melphalan is eliminated from plasma primarily by chemical hydrolysis to monohydroxymelphalan and dihydroxymelphalan. (nih.gov)
  • Aside from these hydrolysis products, no other melphalan metabolites have been observed in humans. (nih.gov)
  • Melphalan primarily distorts the DNA guanine base with an alkyl group monoadduct [ 2 ], particularly at the nitrogen atom 7 of the imidazole ring, and it can also distort DNA with other adducts. (biomedcentral.com)
  • To further describe the safety and tolerability of bendamustine (Benda)/melphalan (Mel) (+/- rituximab) in relapsed (rel)/refractory (ref) diffuse large B-cell lymphoma (DLBCL). (cancer.gov)